COMMUNIQUÉS West-GlobeNewswire

Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
09/05/2019
EXTON, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will [...]
Spectral Announces First Quarter Results
09/05/2019
TORONTO, May 09, 2019 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX: EDT) , a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its [...]
resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness
09/05/2019
Top-line data from both PROTECTOR Phase 3 studies expected in mid-2020 BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of [...]
Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
09/05/2019
PRINCETON, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at the [...]
Chimerix Announces First Quarter 2019 Financial Results and Strategy Update
09/05/2019
– Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir [...]
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors
09/05/2019
UTRECHT, Netherlands, May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today [...]
Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
09/05/2019
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated [...]
Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress
09/05/2019
SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference
09/05/2019
Overview and Update on the Immuno-STAT Platform for Selective Targeting of Tumor-specific T cells CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy [...]
Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
09/05/2019
- Patient enrollment ongoing in COMPARE trial evaluating efficacy and safety of SEL-212 vs. KRYSTEXXA® in patients with chronic refractory gout; interim data expected in 4Q19 - - Preclinical data showing potential for [...]
WishBone Medical Acquires Indiana Based Spinal Systems Company
09/05/2019
Acquisition propels development of WishBone spine solutions for children WARSAW, Ind., May 09, 2019 (GLOBE NEWSWIRE) -- WishBone Medical is pleased to announce the recent purchase of CSpine, Inc., an Indiana based [...]
Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai
09/05/2019
Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI ® IV in China and a Co-Detailing collaboration in Shanghai Lugano, Switzerland, and Beijing, China, May 9, 2019 : Helsinn Group, a Swiss [...]
BioPorto Announces Q1 2019 Report
09/05/2019
May 9, 2019 Announcement no. 6 Q1 2019 Report Highlights FDA application processes for The NGAL Test™ on schedule In the first quarter of 2019 BioPorto focused intensively on driving our clinical studies and preparation [...]
Nexstim Plc: New shares have been registered
09/05/2019
Company announcement, Helsinki, 9 May 2019 at 9.00 AM Nexstim Plc: New shares have been registered Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( " Nexstim " or " Company " ), the targeted neuromodulation company developing and [...]
Terveystalo Plc: Terveystalo Group Interim report 1 January -31 March 2019
09/05/2019
Growth in all customer groups, Attendo integration on track Terveystalo Plc Interim report 9 May 2019 at 9:00 am EEST This release is a summary of Terveystalo's Interim Report for 1 January – 31 March 2019. The full [...]
Three-month interim report (Q1) 2019
09/05/2019
Strong sales growth in Q1 (unaudited) In Q1, ALK had organic growth of 14% and continued to deliver on its growth strategy, which saw accelerated growth in tablet sales of 52% and further stabilisation of its legacy AIT [...]
ObsEva Reports First Quarter 2019 Financial Results
09/05/2019
2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids; MAA submission for nolasiban IVF therapy targeted by year-end GENEVA, Switzerland and BOSTON, MA. (May 9, 2019) – ObsEva SA ( [...]
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
09/05/2019
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
New Study Demonstrates Safety and Effectiveness of the MiniMed(TM) 640G System Reducing Hypoglycemia Compared with Insulin Pump Therapy Without CGM in Type 1 Diabetes
09/05/2019
DUBLIN - May 9, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of the SMILE study in The Lancet Diabetes & Endocrinology . 1 The SMILE study ( S tudy of M [...]

Pages